
Sign up to save your podcasts
Or


Effective management of urinary incontinence (UI) is influenced by patients’ help-seeking behaviours as well as which services are offered by healthcare professionals. To increase awareness, it is important to understand the knowledge, attitudes and beliefs of healthcare practitioners towards urinary incontinence management. This episode will explore varying attitudes to OAB diagnosis and management, and what more can be done to positively influence physician behaviour towards management. In particular, this episode will focus on how technological advances can change OAB management, and the impact this can have.
Disclaimer:
This presentation include products/indications which may not be approved in your country. Physicians should take into account the patient’s individual circumstances and consult the approved product information before prescribing.
Astellas’ products availability, starting dose and indications may vary from country to country. These presentations are prepared solely for education of the healthcare professionals and does not necessarily reflect the opinions or recommendations of the sponsor.
Astellas prohibits the promotion of unapproved drug usage and complies with all applicable laws, regulations, and company policies.
Approval code: INT-M-BET-202106-06
By Astellas PharmaEffective management of urinary incontinence (UI) is influenced by patients’ help-seeking behaviours as well as which services are offered by healthcare professionals. To increase awareness, it is important to understand the knowledge, attitudes and beliefs of healthcare practitioners towards urinary incontinence management. This episode will explore varying attitudes to OAB diagnosis and management, and what more can be done to positively influence physician behaviour towards management. In particular, this episode will focus on how technological advances can change OAB management, and the impact this can have.
Disclaimer:
This presentation include products/indications which may not be approved in your country. Physicians should take into account the patient’s individual circumstances and consult the approved product information before prescribing.
Astellas’ products availability, starting dose and indications may vary from country to country. These presentations are prepared solely for education of the healthcare professionals and does not necessarily reflect the opinions or recommendations of the sponsor.
Astellas prohibits the promotion of unapproved drug usage and complies with all applicable laws, regulations, and company policies.
Approval code: INT-M-BET-202106-06